Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LIVN logo LIVN
Upturn stock ratingUpturn stock rating
LIVN logo

LivaNova PLC (LIVN)

Upturn stock ratingUpturn stock rating
$45.02
Last Close (24-hour delay)
Profit since last BUY2.18%
upturn advisory
Consider higher Upturn Star rating
BUY since 35 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: LIVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

11 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Year Target Price $61.8

Year Target Price $61.8

Analyst’s Price TargetsFor last 52 week
$61.8Target price
Low$32.48
Current$45.02
high$57.35

Analysis of Past Performance

Type Stock
Historic Profit -8.33%
Avg. Invested days 51
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.49B USD
Price to earnings Ratio -
1Y Target Price 61.8
Price to earnings Ratio -
1Y Target Price 61.8
Volume (30-day avg) 11
Beta 0.91
52 Weeks Range 32.48 - 57.35
Updated Date 06/30/2025
52 Weeks Range 32.48 - 57.35
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.07

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -17.42%
Operating Margin (TTM) 15.54%

Management Effectiveness

Return on Assets (TTM) 4.55%
Return on Equity (TTM) -19.7%

Valuation

Trailing PE -
Forward PE 22.99
Enterprise Value 2434509620
Price to Sales(TTM) 1.96
Enterprise Value 2434509620
Price to Sales(TTM) 1.96
Enterprise Value to Revenue 1.91
Enterprise Value to EBITDA 327.96
Shares Outstanding 54525700
Shares Floating 54335396
Shares Outstanding 54525700
Shares Floating 54335396
Percent Insiders 0.38
Percent Institutions 102.65

Analyst Ratings

Rating 4
Target Price 61.8
Buy 4
Strong Buy 4
Buy 4
Strong Buy 4
Hold 3
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

LivaNova PLC

stock logo

Company Overview

overview logo History and Background

LivaNova PLC was formed in 2015 through the merger of Sorin S.p.A. and Cyberonics, Inc. Sorin was founded in 1956 focusing on cardiovascular devices, while Cyberonics was founded in 1987, specializing in neuromodulation therapies.

business area logo Core Business Areas

  • Cardiovascular: Develops and manufactures devices for cardiac surgery and structural heart procedures, including heart-lung machines, oxygenators, and tissue valves.
  • Neuromodulation: Focuses on therapies for neurological diseases, primarily using vagus nerve stimulation (VNS) for treatment-resistant epilepsy and depression.

leadership logo Leadership and Structure

The current CEO is William Kozy. The company operates with a global structure, organized around its two main business units: Cardiovascular and Neuromodulation. Their headquarters are in London, UK.

Top Products and Market Share

overview logo Key Offerings

  • CardioCel: A regenerative tissue patch used in cardiovascular repair and reconstruction. Market share is estimated at around 5-10% within the surgical patch market. Competitors include Baxter (BAX), LeMaitre Vascular (LMAT), and Getinge (GETI_B.ST).
  • VNS Therapy System (for Epilepsy): A vagus nerve stimulation device used to reduce the frequency of seizures in patients with drug-resistant epilepsy. LivaNova holds a significant market share (estimated 50-60%) in the VNS therapy market. Competitors include Medtronic (MDT) and Boston Scientific (BSX), which are developing competitive neuromodulation devices.
  • LifeSpan: A heart-lung machine. Market share data unavailable. Competitors include Medtronic (MDT) and Getinge (GETI_B.ST).

Market Dynamics

industry overview logo Industry Overview

The medical device industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. The neuromodulation market is also growing due to increasing acceptance of these therapies and expanding applications.

Positioning

LivaNova holds a strong position in the VNS therapy market and a competitive position in select cardiovascular device segments. Its competitive advantage lies in its established VNS technology and specialized cardiovascular products.

Total Addressable Market (TAM)

The cardiovascular and neuromodulation markets are estimated to be worth billions of dollars annually. LivaNova is positioned to capture a portion of these markets through its existing product portfolio and pipeline of new products. The Cardiovascular TAM is estimated at $18B, and Neuromodulation at $8B. LivaNova holds a relatively smaller position in both these TAMs.

Upturn SWOT Analysis

Strengths

  • Established VNS technology
  • Specialized cardiovascular products
  • Global presence
  • Strong brand recognition in specific niches

Weaknesses

  • Reliance on VNS therapy for revenue
  • Limited product diversification
  • Relatively small size compared to major competitors
  • Past Legal liabilities

Opportunities

  • Expanding applications of neuromodulation
  • Developing new cardiovascular devices
  • Entering emerging markets
  • Strategic acquisitions and partnerships

Threats

  • Increasing competition from larger medical device companies
  • Regulatory changes and healthcare reforms
  • Product liability claims
  • Technological obsolescence

Competitors and Market Share

competitor logo Key Competitors

  • Medtronic (MDT)
  • Boston Scientific (BSX)
  • Getinge (GETI_B.ST)
  • Baxter (BAX)

Competitive Landscape

LivaNova faces stiff competition from larger, more diversified medical device companies like Medtronic and Boston Scientific. While LivaNova has a strong position in VNS therapy, its overall market share is smaller compared to these giants.

Major Acquisitions

Imthera Medical

  • Year: 2019
  • Acquisition Price (USD millions): 225
  • Strategic Rationale: Expanded LivaNova's portfolio into obstructive sleep apnea (OSA) treatment with the Aura6000 device.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been mixed, with periods of strong growth in neuromodulation offset by challenges in the cardiovascular business.

Future Projections: Future growth is expected to be driven by new product launches in both cardiovascular and neuromodulation, as well as geographic expansion. Analyst estimates vary, but suggest moderate growth in revenue and earnings.

Recent Initiatives: Recent initiatives include the development of new VNS therapy applications, strategic partnerships to expand market access, and cost reduction programs.

Summary

LivaNova has a leading position in neuromodulation via VNS but faces challenges from larger competitors in the cardiovascular market. VNS provides a stable revenue base but growth depends on new applications and geographic expansion. Strategic acquisitions and cost controls are important for future profitability. They must also monitor and adapt to ongoing regulatory changes.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About LivaNova PLC

Exchange NASDAQ
Headquaters -
IPO Launch date 1993-02-10
CEO & Director Mr. Vladimir A. Makatsaria
Sector Healthcare
Industry Medical Devices
Full time employees 2900
Full time employees 2900

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.